Category Archives: Biotech

The critical friend – appointing non-executive directors

Non-executive directors are usual on the boards of most biotech companies. In some cases their appointment may be a condition of the investors but beyond that they bring objectivity and…

Searing temperatures and hot debate at HealthEx London CEO/CFO Forum

On the hottest day on record for over 165 years, 30 CEOs and CFOs from many of the UK’s leading listed life science and healthcare companies made the journey to Westminster,…

The Californian biotech who brought a $100m IPO to UK shores

Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to…

View of an active private life science investor

In March, Jon Moulton increased his shareholding in Redx Pharma as the biotech company successfully completed it’s IPO on London’s AIM. Jon has long experience of turnarounds, having invested in…

From developing highly differentiated ‘best-in-class’ new drugs to IPO

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection. By improving the characteristics of existing drug classes…

Using conformational design to target a $9bn therapeutic market

C4X Discovery, a Manchester-based, AIM-listed Company which uses an NMR-based technique to optimise drug discovery, possess a unique drug discovery technology has the potential to cut preclinical development times and cost by…

Investing in making the undruggable druggable

PhoreMost Ltd, a biopharmaceutical company focused on increasing the diversity and affordability of novel therapeutics, announced in May that it has been selected to receive a funding award of £1.4M…

May 2015 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The May issue is the third of 6 bi-monthly publications in 2015 aimed at providing insight,…

How to achieve a successful life science exit

What follows is the final summary from the 22 April Biotechs and the City evening event, in which over 80 executives from across London, Cambridge and Oxford attended the ‘From…

Where to list your life science company and why?

What follows is the second summary from our evening panel discussion ‘From idea to IPO’ that took place at our most recent Biotechs and the City networking event. Panelists: Maina…